Bio Age Labs, Inc. BIOA
We take great care to ensure that the data presented and summarized in this overview for BioAge Labs, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in BIOA
Top Purchases
Top Sells
About BIOA
Insider Transactions at BIOA
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jan 16
2026
|
Dov A Md Goldstein Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,542
+12.01%
|
$14,168
$4.38 P/Share
|
|
Jan 13
2026
|
Kristen Fortney Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
233,107
-19.26%
|
$4,195,926
$18.12 P/Share
|
|
Jan 13
2026
|
Dov A Md Goldstein Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
27,000
-17.36%
|
$513,000
$19.88 P/Share
|
|
Jan 13
2026
|
Dov A Md Goldstein Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
27,000
+35.34%
|
$216,000
$8.39 P/Share
|
|
Jan 02
2026
|
Paul D Rubin Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
7,433
-100.0%
|
$89,196
$12.85 P/Share
|
|
Jan 02
2026
|
Paul D Rubin Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,433
+35.6%
|
$37,165
$5.34 P/Share
|
|
Dec 09
2025
|
Paul D Rubin Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
18,000
-100.0%
|
$216,000
$12.0 P/Share
|
|
Dec 09
2025
|
Paul D Rubin Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
18,000
+50.0%
|
$108,000
$6.57 P/Share
|
|
Dec 04
2025
|
Paul D Rubin Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
68,897
-100.0%
|
$688,970
$10.19 P/Share
|
|
Dec 04
2025
|
Paul D Rubin Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
68,897
+50.0%
|
$275,588
$4.11 P/Share
|
|
Oct 03
2024
|
Vijay Satyanand Pande |
BUY
Open market or private purchase
|
Indirect |
25,306
+2.21%
|
$480,814
$19.9 P/Share
|
|
Oct 02
2024
|
Vijay Satyanand Pande |
BUY
Open market or private purchase
|
Indirect |
67,096
+5.78%
|
$1,274,824
$19.73 P/Share
|
|
Oct 01
2024
|
Vijay Satyanand Pande |
BUY
Open market or private purchase
|
Indirect |
126,793
+10.99%
|
$2,409,067
$19.73 P/Share
|
|
Sep 27
2024
|
Shane Barton Principal Accounting Officer |
BUY
Open market or private purchase
|
Direct |
2,632
+50.0%
|
$47,376
$18.0 P/Share
|
|
Sep 27
2024
|
Cormorant Asset Management, LP |
BUY
Open market or private purchase
|
Indirect |
450,000
+21.64%
|
$8,100,000
$18.0 P/Share
|
|
Sep 27
2024
|
Cormorant Asset Management, LP |
BUY
Conversion of derivative security
|
Indirect |
1,179,529
+50.0%
|
-
|
|
Sep 27
2024
|
Patrick G Enright |
BUY
Open market or private purchase
|
Indirect |
400,000
+18.95%
|
$7,200,000
$18.0 P/Share
|
|
Sep 27
2024
|
Patrick G Enright |
BUY
Conversion of derivative security
|
Indirect |
1,310,589
+50.0%
|
-
|
|
Sep 27
2024
|
Vijay Satyanand Pande |
BUY
Open market or private purchase
|
Indirect |
900,000
+50.0%
|
$16,200,000
$18.0 P/Share
|
|
Sep 27
2024
|
Vijay Satyanand Pande |
BUY
Conversion of derivative security
|
Indirect |
2,113,975
+43.64%
|
-
|
Last 12 Months Summary
Buy / Acquisition
125K
Shares
From
2
Insiders
| Exercise of conversion of derivative security | 125K shares |
|---|
Sell / Disposition
354K
Shares
From
3
Insiders
| Open market or private sale | 354K shares |
|---|